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contact dermatitis: a brief preview
Increasing numbers of individuals 
suffer from allergic dermatitis caused 
by exposure to the large variety of 
low-molecular-weight compounds pres-
ent in the environment. Exposure to such 
chemicals can induce either an immune-
based delayed-type hypersensitivity 
(DTH) reaction or an irritant reaction. 
The DTH reactions are often occupation-
ally related and are a common hazard for 
hairdressers, nurses, cleaners, and metal 
workers. In practice, it can be difficult to 
distinguish DTH from irritant reactions 
(Brasch et al., 1992).
Immunological dogma on the 
pathophysiology of contact dermatitis
The historic publication by Landsteiner 
and Jacobs (1935) and later articles 
(Aleksic et al., 2007) confirm that the 
binding of a small molecule (hapten) 
to one of the many nucleophilic amino 
acids present in intra- or extracellular 
proteins to generate a hapten–protein 
complex is an essential primary step 
in the development of subsequent 
immune-mediated derma titis. The 
hapten–protein complex is usually 
internalized and processed by antigen-
presenting cells (APCs) such as dendritic 
cells and expressed as an antigen (Ag) 
in combination with major histo-
compatibility complex (MHC) mole-
cules on the APC surface. The dendritic 
cells in turn migrate to draining lymph 
nodes, where they present the anti-
gen to naive T cells in the context of 
an MHC/T-cell receptor complex. 
This results in the generation of anti-
gen-specific memory T-cell subsets. 
These cells migrate to the skin, where, 
on exposure to the antigenic determ-
inant, they may become activated, 
leading to tissue damage seen as a DTH 
inflammatory reaction. In this elicitation 
phase, the antigenic repertoire of blood 
and skin T cells plays a decisive role in 
determining whether an immune-based 
disease takes place.
The principles, as outlined in 
Figure 1 (Hennino et al., 2005), 
show that the migration of epidermal 
Langerhans cells after contact with 
the potential allergenic chemical is an 
important step in sensitization. This prin-
ciple has been shown to be true in both 
in vivo mouse experiments and ex vivo 
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human organotypic skin explant culture 
(De Silva et al., 1996). Interestingly, the 
latter model can be used to distinguish 
true allergens from skin irritants (Lehé 
et al., 2006). The activation of sensitized 
T cells in the skin is also dependent on 
optimal interaction between an APC 
and the small molecule. Based on 
this principle, the patch test has been 
developed for diagnosing whether a 
patient has been previously sensitized 
to a specific chemical. However, patch 
irritants may give false-positive reac-
tions, positive patch reactions may occur 
in the absence of relevant clinical find-
ings, or the relevant allergen may not 
be the one that is tested (McNamee et 
al., 2008). In this context (the activa-
tion of allergen-specific T cells leading 
to contact dermatitis), Jenkinson et al. 
(2010, this issue) elegantly illustrate the 
importance of chemical immunology in 
elucidating the immunological mecha-
nisms of contact dermatitis. The work is 
commendable and important.
Combining basic chemistry with 
classic immunology, Jenkinson et al. 
investigated how small chemicals interact 
with T cells using p-phenylenediamine 
(PPD), a known contact sensitizer, as a 
model chemical. The immuno stimulatory 
effects of PPD in mice are thought to be 
dependent on the generation of cutan-
eous secondary oxidation products that 
result in the formation of Bandrowski’s 
base, a derivative of three conjugated 
PPD molecules. Bandrowski’s base is 
also a potent mitogen for human T cells 
but does not distinguish between aller-
gic and tolerant individuals; however, in 
tolerant individuals this response is not 
translated into an allergic reaction. In 
contrast, T-cell responses (as measured 
by the lymphocyte transformation test) to 
PPD are restricted to allergic individuals. 
Taken together, these data indicate that 
primary oxidation products of PPD form 
the Ag determinants in humans.
essence of the findings
To determine the nature of possible anti-
genic determinants, the authors investi-
gated the binding of PPD to human serum 
albumin (HSA) as the carrier protein. 
Incubating PPD with HSA resulted in the 
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specific binding of PPD to cysteine-34 of 
HSA. To determine whether PPD–HSA 
was antigenic, the authors assayed the 
activity of PPD and PPD–HSA on T-cell 
proliferation, using the lymphocyte trans-
formation test (LTT) and the proliferation 
and cytokine secretion profile of CD4+, 
CD8+, and CD4/8 double-positive T-cell 
clones isolated by stimulating T cells 
from the blood of allergic volunteers 
using PPD or PPD–HSA.
The investigators confirmed that PPD 
was active in the LTT and that it acti-
vated CD4+, CD8+, and CD4/8 double-
positive T-cell clones (cell proliferation, 
cytokine synthesis, and activation of 
cytotoxic CD8+ cells) at nontoxic con-
centrations when Epstein–Barr virus–
transformed B cells were used as the 
Ag-presenting cell. Ag presentation 
appeared to involve three mechanisms: 
(i) covalent binding to protein (probably 
MHC associated) with no Ag process-
ing, (ii) binding to protein followed by 
antigen processing, and (iii) direct weak 
binding to MHC-associated molecules.
PPD–HSA was more active than PPD 
in the LTT but much less active when 
T-cell clones were used (cell proliferation 
and cytokine production). PPD–HSA did 
not activate CD8+ cytotoxic cells. Unlike 
PPD, PPD–HSA had to be internalized 
and processed by the APC to activate the 
T-cell clones.
missing links
It should be borne in mind that the article 
by Jenkinson et al. deals primarily with 
the T-cell-mediated inflammatory phase 
of a DTH reaction. Although the aims 
of the chemical studies were achieved, 
the data presented using blood cells and 
T-cell clones should be expanded for 
more patients by generating clones from 
blood cells and patch-tested skin biop-
sies. Not only should the analyses focus 
on Ag specificity of T cells per se but the 
T cells should be divided into cutaneous 
lymphocyte antigen–positive and –nega-
tive populations.
Future work should also be aimed at 
generating longitudinal data to allow an 
intra-clonal comparison of the param-
eters assayed (e.g., cytokine production, 
LTT, Ag processing dependent or inde-
pendent) in relation to the intensity of 
the patch test result. An intriguing fea-
ture of this T-cell-based study is that the 
cytokine profile of the Ag-specific T-cell 
clones is primarily a type 2 secreting 
cytokine profile instead of the type 1 pro-
file expected for allergen-specific DTH 
clones. These studies should be followed 
by conducting studies that measure the 
humoral response and explore its role in 
DTH-based pathology.
Future and scope
First, the data support previous work 
indicating that small molecules are like-
ly to generate fewer Ag determinants in 
vivo than might be expected on the basis 
of binding studies with isolated amino 
acids or small peptides. Although the 
investigators report that PPD–HSA com-
plexes are more active than PPD in the 
LTT (presumably using peripheral blood 
mononuclear cells), PPD was much more 
active in stimulating the T-cell clones (in 
respect to proliferation and cytokine 
synthesis and expression of CD107a on 
CD8+ clones) than PPD–HSA. This may 
indicate that the clones were not typical 
of T-cell populations found in vivo or that 
the use of transformed B cells as APCs 
might have selectively modified respons-
es of the T-cell clones to the presented 
Ag. At least for the system used, the data 
indicate that PPD binding to protein on 
B cells generates Ag determinants that 
are much more active than PPD bound 
to a soluble protein. It may be that the 
analysis of hapten conjugates formed 
after incubation of PPD with APCs will 
yield yet more relevant information than 
that obtained using isolated proteins, 
peptides, or amino acids.
Second, a positive relationship 
between the cytokine profile of blood 
and patch test–derived T cells and the 
severity of the DTH reaction might be 
expected. The patch test is classically 
considered to reveal a T helper type 1 
(Th1) reaction. However, in this and 
other studies, blood-derived T cells 
and clones synthesize and release in 
a largely Th2 pattern, independent of 
the T-cell type (CD4, CD8, or mixed). 
Cytotoxic CD8+ cells are generally con-
sidered responsible for tissue damage 
during DTH reactions (the investigators 
report that CD8+ cells were activated by 
PPD but not by PPD–HSA). On the other 
hand, CD4+ cells are usually thought to 
regulate development of tolerance, and it 
will be interesting to learn whether some 
of the CD4+ clones are of a T-regulatory 
phenotype. To clarify the latter paradigm 
Figure 1. Pathophysiology of allergic contact dermatitis. (Left) Sensitization phase (afferent phase). 
Haptens penetrate the epidermis (step 1) and are taken up by epidermal cells, including skin. Dendritic 
cells (DCs) migrate to the draining lymph nodes (step 2), where they present haptenated peptides to 
both CD8+ effector T cells and downregulatory CD4+ T cells (step 3). Specific T-cell precursors clonally 
expand in draining lymph nodes, recirculate via the blood, and migrate to tissues, including the skin 
(step 4). (Right) Elicitation phase (challenge phase, efferent phase). When the same hapten is applied to 
the skin, it is taken up by epidermal cells, including skin DCs and keratinocytes (step 5), which present 
haptenated peptides to specific T cells. Activation of CD8+ cytotoxic T lymphocytes induces apoptosis of 
keratinocytes and production of cytokines and chemokines by skin resident cells (step 6). This leads to 
the recruitment of leukocytes from the blood to the skin. CD4+ T cells may block activation/expansion of 
CD8+ effectors in lymph nodes during sensitization and in the skin during the elicitation phase of contact 
hypersensitivity (steps 3 and 7). Reproduced with permission, under a Creative Commons license, from 
Hennino et al., 2005.
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in relation to the disease, it is essential to 
compare the activity of T cells from blood 
and patch test sites simultaneously in the 
same patient, as mentioned above.
Third, and most important, in light 
of allergic patients’ hapten-specific Th2 
cytokine profile, additional studies should 
measure Ab titers to hapten/hapten-
bound protein complexes. Such studies 
would open the door for immuno logical 
studies on the cooperative effects of Abs, 
antigen-specific T cells, and immune 
complexes and their role in the path-
ology of contact derma titis. This raises 
the possibility that haptens not only gen-
erate hapten-specific T cells but also can 
initiate the production of hapten-specific 
Abs. Abs specific for low-molecular-
weight compounds have been reported 
previously (Das et al., 1980; Amos et al., 
1978). In the latter case it can be postu-
lated that, in addition to T-cell-mediated 
hypersensitivity reactions, hapten–Ab 
complexes can give rise to type III hyper-
sensitive reactions.
concluding remarks
These immunochemical studies do not 
necessarily ring the death knell for the 
patch test. However, the data should 
certainly encourage other researchers to 
develop more objective parameters for 
improving the patch test, stimulate the 
development of novel alternative in vitro 
tests, and enhance the understanding 
of structure–activity relationships in the 
pathophysiology of contact dermatitis.
The work reported in this and similar 
studies has opened the door to apply-
ing combined chemical immunological 
techniques to (i) study the different 
types of chemical modification of small 
chemicals that render them allergenic, 
nonallergenic, or simple irritants and (ii) 
elucidate the mechanism of chemically 
induced dermatitis in depth compared 
with that of irritant contact dermatitis.
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Multiple Genes and Locus 
Interactions in susceptibility  
to Vitiligo
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Refining the position of loci on chromosomes 7 and 9 previously linked with 
generalized vitiligo or vitiligo-associated autoimmune diseases presenting in 
families has been performed by high-density single-nucleotide polymorphism 
(snP) genotyping. Investigation of the genetic interaction among these loci (and 
with a previously identified susceptibility gene, NLRP1, on chromosome 17) as 
risk factors for vitiligo demonstrates the complex nature of this disease.
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The biological basis of the depigment-
ing condition known as vitiligo has 
been an intractable problem to con-
front. The difficulty lies in the absence 
of the cells responsible for the disease, 
posing the conundrum of how to study 
something that isn’t there. Patients pre-
senting with vitiligo have a progressive 
loss of melanocytes, predominantly in 
areas of skin subject to physical abra-
sion or at pressure points, leading to 
white patches appearing on the body. 
In normal physiological circumstances, 
melanin pigment is generated by the 
melanocytes and transferred to the 





of PPD depend on 
the generation of 
secondary oxidation 
products in skin.
